Articles

Changes in β-amyloid (Aβ) and hyperphosphorylated tau (T) in brain and cerebrospinal fluid (CSF) precede Alzheimer's disease (AD) symptoms, making the CSF proteome a potential avenue to understand disease pathophysiology and facilitate reliable diagnostics and therapies. Using the AT framework and a three-stage study design (discovery, replication, and meta-analysis), we identified 2,173 analytes (2,029 unique proteins) dysregulated in AD. Of these, 865 (43%) were previously reported, and 1,164 (57%) are novel.

The article discusses advancements in using 3D models and human iPSC-derived microglia to study neurodevelopment and neurological disorders, highlighting their potential for understanding brain development, microglial functions, and disease mechanisms. It also explores various models, including organoids and xenotransplantation, and their applications in studying conditions like Alzheimer’s, Parkinson’s, and autism.

Real-world evidence can supplement clinical trial data to optimize Alzheimer’s disease care by aiding early patient identification and assessing drug effectiveness and safety in everyday use in diverse clinical settings/populations. This information helps inform clinical practice guidelines and supports the development of tools for timely diagnosis and personalized treatment strategies.

The article discusses the role of gut dysbiosis, bacterial amyloids, and metabolic diseases in the development and progression of Alzheimer's disease (AD). It highlights the bidirectional relationship between the gut microbiome, inflammation, and metabolic disorders, and how these interconnected pathways contribute to neurodegeneration. The review explores potential therapeutic strategies targeting the gut-brain-metabolic axis to mitigate AD progression.